Related Experiment Videos
Risk of complications of atrial fibrillation
A Capucci1, G Q Villani, D Aschieri
1Division of Cardiology, Ospedale Civile, Piacenza, Italy.
Insights
Atrial fibrillation increases risks of stroke and sudden death. Warfarin anticoagulation effectively reduces embolism risk, while certain antiarrhythmic drugs can paradoxically worsen arrhythmias.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Atrial fibrillation (AF) presents significant risks including thromboembolism, hemodynamic compromise, and arrhythmogenesis.
- Annual embolization incidence in chronic AF is approximately 5%, with stroke being a major concern.
- AF-related hemodynamic issues stem from loss of atrial contraction, irregular ventricular rhythm, and rapid rates.
Purpose of the Study:
- To review the major complications associated with atrial fibrillation.
- To discuss the efficacy of anticoagulation in reducing thromboembolic events.
- To highlight proarrhythmic risks associated with AF treatments.
Main Methods:
- Literature review of atrial fibrillation complications.
- Analysis of anticoagulation therapies (warfarin vs. aspirin) for embolism prevention.
- Evaluation of drug-induced proarrhythmias and hemodynamic compromise.
Main Results:
- Warfarin significantly reduces the risk of embolism and stroke compared to aspirin or placebo.
- Hemodynamic compromise can result from irregular ventricular rhythm and excessively rapid rates during AF.
- Proarrhythmias, such as Torsades de pointes and 1:1 atrial flutter, are recognized complications of AF treatment.
Conclusions:
- Anticoagulation, particularly with warfarin, is crucial for managing thromboembolic risk in atrial fibrillation.
- Understanding and mitigating proarrhythmic effects of antiarrhythmic drugs is essential for patient safety.
- Comprehensive management of atrial fibrillation requires addressing thromboembolic, hemodynamic, and arrhythmogenic risks.
Abstract:
Atrial fibrillation is associated with three major risk of complications: thromboembolism, hemodynamic compromise, and arrhythmogenesis. In patients with chronic atrial fibrillation the incidence of embolization is about 5% per year. The risk of embolism and in particular of stroke can be reduced by warfarin anticoagulation. Aspirin is generally less effective than warfarin, although it is probably more effective than placebo. The hemodynamic complications which may occur during atrial fibrillation are mainly due to the loss of effective atrial contraction, the irregular ventricular rhythm, and the possible excessively rapid ventricular rate. Sudden death is a recognized manifestation of Wolff-Parkinson-White syndrome and is considered to be precipitated by atrial fibrillation in the majority of patients. Torsades de pointes is perhaps the most widely recognized proarrhythmia associated with treatment of atrial fibrillation, especially with 1A antiarrhythmic drugs and sotalol. The chronic treatment with type 1C drugs in 3.5%-5% of patients may induce atrial flutter with 1:1 conduction with significant hemodynamic compromise.